CAD

Across TCGA pan-cancer cohorts, CAD mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CAD data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CAD mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CAD expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, LSCC, and LUAD are the cancer types where CAD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.379	0.723	.003	39	view →
LSCC	OS	Quartile	II,III,IV	1.000	0.588	.003	29	view →
LUAD	OS	Median	All	0.767	1.000	.004	19	view →
PDAC	DFS	Quartile	II,III,IV	0.218	0.503	.007	13	view →
HNSC	OS	Quartile	All	0.795	0.909	.037	3	view →
UCEC	OS	Quartile	All	0.889	1.000	.038	2	view →
GBM	DFS	Quartile	All	0.624	0.830	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CAD–CCRCC (DFS)

Open the CCRCC breakdown →